I. Dr. Patel opened the meeting at 8:30am
II. Roll Call was taken. Drs. Florence and Vergara-Rodriguez were excused from attendance.
III. No conflicts of Interest
IV. October meeting minutes were unanimously approved.
V. Public Testimony

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Product</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cassandra Lickert, MD</td>
<td>Myfembree</td>
<td>Myovant Sciences, Inc.</td>
</tr>
<tr>
<td>Timothy Birner, PharmD, MBA</td>
<td>Lybalvi</td>
<td>Alkermes</td>
</tr>
<tr>
<td>Jenish Patel, PharmD.</td>
<td>Invega Hafyera</td>
<td>Janssen</td>
</tr>
<tr>
<td>George Vass, PharmD</td>
<td>Quilpta</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Ryan Norman</td>
<td>AirDuo</td>
<td>Teva</td>
</tr>
<tr>
<td>*Michael Feld, MD</td>
<td>Qelbree</td>
<td>Michael Feld, MD SC</td>
</tr>
</tbody>
</table>

VI. There none PDL Drug Appeals for this meeting.
VII. New Drug Appeals-
   a. Qelbree (Viloxazine HCL Cap ER)
      Michael Feld, MD spoke on behalf of the manufacturer and himself to recommend making Qelbree preferred on the PDL. Dr. Goyal asked Dr. Feld about any conflicts of interest or relationships with the drug manufacturer he may have. Dr. Feld responded that indeed he was on their speaker list but was speaking today as himself and for his personal interest and was not being reimbursed for the testimony. The board was reminded that both guanfacine and clonidine are preferred non-stimulant options in the ADHD class. Dr. Berkowitz spoke about the need to increase access to non-stimulant options. Dr. Berkowitz motioned for the Qelbree to be made preferred with a PA. Dr. Albers seconded the motion. The motion carried and the board recommended that Qelbree become preferred with a PA.

VIII. Ryan Rodriguez, PharmD. presented each class monograph.
     a. Antiasthmatics-Adrenergics-Dr. Rodriguez presented a clinical overview of the class noting that the current guideline recommends one of two pathways. The first includes combination inhalers as the preferred approach. This is the most widely accepted. The second recommends starting with a short acting beta-agonist. Dr. Rodriguez explained that the agents are relatively equal in safety and efficacy. Dr. VanSteenburg recommended that generic Symbicort be made preferred on behalf of the MCOs. She also recommended adding Anoro Ellipta as preferred due to the once daily dosing. The question was raised about having a product with 3 drugs as preferred and Dr. Rodriguez wondered if that would encourage patients moving too quickly through the recommended tracks. Further discussion followed about the pros and cons of agents in the class. Dr. Shaw moved to have Anoro Ellipta a preferred option for once a day dosing and it was seconded by Garry Moreland. The motion carried.
b. Antiasthmatics-Anticholinergics-Dr. Rodriguez presented the clinical overview of the class. Noting that this is class is generally all long-acting products except for ipratropium. There is currently no conclusive evidence to support one product being more efficacious than the others in the class. All are generally well tolerated and safe. It was noted that while ipratropium is available generically it must be dosed 4 times per day and the others are once or twice a day. Garry Moreland requested clarification as to why some forms of Spiriva were preferred while others were not. A discussion followed as to whether all forms should be preferred. Dr. VanSteenburg recommended making Incruse Ellipta preferred on behalf of the MCOs to offer consistency across the classes. Dr. Albers moved to make Incruse Ellipta preferred and Dr. Berkowitz seconded. The motion carried. Mr. Moreland then made the motion to make all forms of Spiriva preferred and it was seconded by Dr. Albers and the motion carried.

IX. New Drug Initial Review
a. Lybalvi (Olanzapine-Samidorphan L-malate)- Dr. Rodriguez presented a review of the product. It was noted that this product may be better than the others in the class when metabolic syndrome is an issue. It also carries a contraindication for patients on opioids. Dr. Berkowitz spoke to the need for options for patients with significant weight gain. The board requested that drug testing be considered in PA criteria. Dr. Berkowitz motioned that Lybalvi be preferred with a PA. Mr. Moreland seconded the motion. The motion carried.

b. Invega Hafyera- Dr. Rodriguez presented a review of the product. It was noted that since this is a very long-acting product, tolerability must be demonstrated prior to initiation. Dr. Berkowitz noted that this would be something used after stability on the shorter acting forms was demonstrated along with adherence. He also noted that it should not be dosed with no follow-up in the dosing interim. Dr. Goyal noted that side effects can be present and asked if an antidote was available should a bad reaction occur. There is no known antidote. Donna Clay noted that the Department gets more PA requests for Sustena than Trinza and has had no requests for Hafyera to date. Dr. Berkowitz moved to make Invega Hafyera preferred with PA. Mr. Moreland seconded the motion. The motion carried with Dr. Goyal abstaining.

c. Myfembree (Regugolix-Estradiol-Norethindrone Acetate)- Dr. Rodriguez gave an overview of the product. It was noted that the drug is used to decrease heavy menstrual flow in patients with uterine fibroids. It is limited to 2 years of therapy due to bone density concerns. Dr. Patel moved to make this product preferred with PA to place it on equal footing with the comparable product already on the PDL. Dr. Shaw seconded the motion. The motion carried.

d. Qulipta (Atogepant)- Dr. Rodriguez presented an overview of the product. This is a once daily product for prevention of migraine. Mr. Moreland moved for preferred with PA. Dr. Berkowitz seconded the motion. The motion carried with Dr. Patel voting nay and Dr. Albright abstaining.

X. Future Agenda Preview-Sheri Dolan shared that the Classes for the 2022 meetings will be:

April 14, 2022- ADHD Agents and Inhaled Aminoglycosides

July 14, 2022-TBD (announced at the April meeting)

October 13, 2022-Biologic Response Modifiers

XI. Provider Requested Reviews-None for this meeting
XII. Department Update-Jose Jimenez thanked everyone for their work on this board. COVID-19 vaccines, home tests and monoclonal antibodies coverage were briefly discussed with Provider Notices to follow as applicable.

XIII. Adjournment-Dr. Patel adjured the meeting at 10:24am.

Attendees
The names of board members and speakers are bolded.

Panelist List
1. Alyssa Stephenson
2. Sheri Dolan
3. Cynthia VanSteenburg
4. Jose Jimenez
5. Donna Clay
6. Arvind Goyal
7. Garry Moreland
8. Ryan Rodriguez
9. Maurice Shaw
10. Janet Albers
11. Deborah Albright
12. Jennifer DeWitt
13. Heather Freeman
14. Mary Moody
15. Mahesh Patel
16. Paul Berkowitz

Attendee List
1. Alissa Derza
2. Brooke Wilkins
3. Cassandra Lickert
4. Chase Williams
5. Chintan Patel
6. Chris Stanfield
7. Dan Murphy
8. Doug Johnson
9. George Vass
10. Glenn Cornish
11. Jason Vandervest
12. Jenish Patel
13. Jenny Carrell
14. JJ Roth
15. Karen Floeder
16. Ken Ring
17. Laura Schanen
18. Lisa Tracz
19. Matthew Smith
20. Michael Feld
21. Michael Hawks
22. Michael Holmes
23. Opeoluwa Fagbemi
24. Robert Pearce
25. Robert Wright
26. Russell Verney
27. Ryan Norman
28. Sakib Hassan
29. Sara Gao
30. Scott Miller
31. Steven Berardino
32. Sunny Hirpara
33. Susie Brown
34. Tammy Bima
35. Thomas Erickson
36. Tiawana Parker
37. Timothy Birner
38. Waad Nader
39. Zhen Ou